非诺贝特联合瑞舒伐他汀治疗高危混合性高脂血症的疗效及安全性评价  

Efficacy and Safety Evaluation of Fenofibrate Combined with rosuvastatin in the Treatment of High-Risk Mixed Hyperlipidemia

作　　者：马腾龙 MA Tenglong(Pharmacy Department, Qinghai Hospital of Traditional Chinese Medicine, Xining 810000, China)

机构地区：[1]青海省中医院药剂科

出　　处：《长春中医药大学学报》2019年第5期946-949,共4页Journal of Changchun University of Chinese Medicine

摘　　要：目的比较非诺贝特联合瑞舒伐他汀治疗与非诺贝特单药治疗高危混合性高脂血症患者的效果及安全性评价。方法选取中医院混合型高血脂症患者57例,随机分为瑞舒伐他汀组(10 mg/d,n=28)和非诺贝特联合瑞舒伐他汀治疗组(瑞伐他汀10 mg/d+非诺贝特200 mg/d,n=29),疗程均为6个月。比较2组治疗前后血脂水平、肝功能以及不良反应。结果经过6个月的治疗,联合用药组与瑞舒伐他汀单用比较,差异有统计学意义(P <0.05);非诺贝特联合瑞舒伐他汀治疗可明显降低三酰甘油(TG)、总胆固醇(TC)、低密度脂蛋白(LDL-C),且提高高密度脂蛋白(HDL-C),治疗前后的变化具有统计学意义(P <0.05);联合治疗组治疗后的TC,TG,LDL,HDL达标率均显著高于瑞舒伐他汀组,差异具有统计学意义(P <0.05)。结论非诺贝特联合瑞舒伐他汀治疗混合型高脂血症起效快、作用明显、安全有效。Objective To compare the efficacy and safety of fenofibine combined with rosuvastatin in the treatment of high-risk mixed hyperlipidemia with fenofibrate monotherapy. Methods A total of 57 patients with mixed hyperlipidemia in the hospital were randomly divided into the resuvastatin group (10 mg/d, n = 28) and the fenofibrate combined with rosuvastatin group (resuvastatin 10 mg/d+fenofibrate 200 mg/d, n = 29), the course of treatment is 6 months. Blood lipid levels, liver function, and adverse reactions were compared between the two groups before and after treatment. Results After 6 months of treatment, there was significant difference between the combined treatment group and resuvarastatin alone (P < 0.05), fenofibrate combined with resuvarastatin could significantly reduce the total cholesterol (TC), low density lipoprotein (LDL-C) of (TG), and increase the level of high density lipoprotein (HDL-C), and the changes before and after treatment were statistically significant (P < 0.05), and the results showed that fenofibrate combined with resuvarastatin could significantly decrease the total cholesterol LDL of TG and increase the level of high density lipoprotein (LDL) before and after treatment (P < 0.05). The standard rate of TC, TG, LDL, HDL in the combined treatment group was significantly higher than that in the resuvarastatin group (P < 0.05). Conclusion Fenofibrate combined with rosuvastatin in the treatment of mixed hyperlipidemia has a fast onset, effective effect, and is safe and effective.

关 键 词：高脂血症 瑞舒伐他汀 非诺贝特 

分 类 号：R589[医药卫生—内分泌]